Pandemic profiteering: Pfizer to earn a whooping $54 billion by year’s end, thanks to COVID-19

09/09/2022 / By Belle Carter

Global health authorities collaboratively approved Big Pharma vaccines and other treatments – despite adverse events and insufficient trials – to “cure” the Wuhan coronavirus (COVID-19). Nearly two years after the initial vaccine rollout, the number of cases are still big and the balance of Big Pharma’s bank accounts are even bigger.

Pfizer alone is predicted to reap an astonishing $54 billion in revenue by year-end.

The pharmaceutical company is to gain $32 billion in profits from the COVID-19 injections and another $22 billion from Paxlovid, the pill used to treat COVID-19 but can cause the virus to “rebound.”

“Ironically, part of what makes the treatments so profitable is the fact that they don’t do what they’re supposed to, which is to prevent and effectively treat COVID-19,” American alternative medicine proponent Dr. Joseph Mercola said.

Vaccinated people still get infected despite being injected and boosted, and could still transmit the disease to others.

“While it is hoped this will be the case, the scientific community does not yet know if the Pfizer’s COVID-19 vaccine will reduce such transmission,” said the Food and Drug Administration when asked whether Pfizer’s COVID-19 jabs would protect against transmission of the virus.

Mercola further pointed out that Pfizer profits from the vaccine and then when the shots won’t work, the pharma gains more by selling the Paxlovid to further “treat” the infection. President Joe Biden was reported to have a “rebound” infection due to the said pill and he’s not the only one.

Some patients who took the pill after testing positive for coronavirus have reported the same phenomenon: Days after they finished a five-day course of the oral drug and felt better, their COVID symptoms or a positive test result returned.

“This means multiple courses of the drug are often necessary – which is bad news for the public, but great news for Pfizer and its shareholders,” Mercola stated.

Meanwhile, Pfizer is not going to stop basking in the glory of the lucrative industry. It has expressed plans to aggressively expand the COVID vaccine’s use of mRNA technology to treat rare genetic diseases of the liver, muscle and central nervous system through collaboration with Beam Therapeutics, a biotechnology company conducting research in gene therapies and genome editing.

Pfizer CEO Albert Bourla said they hope to reduce the time to produce new vaccines from three months to two months as it explores automated solutions to produce mRNA in collaboration with Codex DNA. Pfizer is also developing a shingles vaccine with BioNTech.

HHS purchases 105 million more doses of Pfizer’s COVID-19 vaccine

According to Mercola, Pfizer vaccines dominate 70 percent of the U.S. and European markets, while Paxlovid has become a standard treatment choice in hospitals.

The U.S. government has disposed of 82.2 million expired COVID-19 doses as of mid-May. But it didn’t deter the Department of Health and Human Services (HHS) to purchase another 105 million doses of Pfizer’s COVID-19 shot for $3.2 billion, thanks to the taxpayers’ money.

Mercola emphasized that contracts are almost exclusively slanted in Pfizer’s favor and they do not have any financial liability for injuries and deaths, and it appears this indemnification applies even if they were to be found guilty of fraud. (Related: How Pfizer profited from the pandemic.)

“It is the public that stands to lose in this deal, as they’re inundated with a new push to get injected with yet another COVID-19 shot, despite their continued failures,” Mercola stated.

Pfizer claims that its new booster jabs will work better than its past versions, with one option being considered to target only the omicron variant, while the other option targets the strain in the original shot along with the omicron variant.

Analysts are saying that the prospect of repeated boosters is exactly what Big Pharma investors are looking forward to.

“Hopefully, we could be giving it annually and maybe for some groups that are high-risk more often,” Bourla told investors this year. “Then you have the treatment [Paxlovid] that will, let’s say, resolve the issues of those that are getting the disease.”

Visit BigPharmaNews.com for more stories about Big Pharma profiting from the “plandemic.”

Watch this video about the corrupt medical alliance that profited from this orchestrated COVID-19 catastrophe.

This video is from the Prisoner channel on Brighteon.com.